Exploring the Role of GM-CSF in the Host Response to C. difficile Infection by Frank, Charles
	  EXPLORING	  THE	  ROLE	  OF	  GM-­‐CSF	  IN	  THE	  HOST	  RESPONSE	  TO	  C.	  DIFFICILE	  INFECTION	  
Charles	  Frank	  
ABSTRACT	  
	   Clostridium	  difficile	  infection	  is	  increasingly	  dangerous	  and	  costly	  worldwide,	  yet	  
the	  host	  response	  to	  the	  disease	  is	  poorly	  understood.	  Recent	  work	  has	  shed	  some	  light	  
on	  the	  immune	  pathways	  involved	  in	  combating	  C.	  diffiicle-­‐induced	  colitis,	  highlighting	  
innate,	  pro-­‐inflammatory	  signaling.	  In	  addition,	  it	  has	  been	  shown	  that	  the	  host	  
response	  is	  characterized	  by	  leukocyte	  infiltration	  into	  the	  intestinal	  epithelium.	  
Granuloctye-­‐macrophage	  colony-­‐stimulating	  factor	  (GM-­‐CSF)	  is	  a	  cytokine	  that	  
promotes	  leukocyte	  production	  and	  maturation,	  and	  has	  a	  role	  in	  inflammatory	  
signaling.	  In	  this	  work,	  we	  sought	  to	  determine	  the	  effect	  that	  loss	  of	  GM-­‐CSF	  signaling	  
has	  on	  the	  intestinal	  innate	  immune	  response	  to	  C.	  difficile	  infection.	  Mice	  were	  made	  
susceptible	  to	  infection	  via	  antibiotic	  treatment,	  treated	  with	  anti-­‐GM-­‐CSF	  antibody	  to	  
deplete	  GM-­‐CSF	  signaling,	  and	  infected	  with	  the	  630g	  strain	  of	  C.	  difficile.	  We	  found	  that	  
anti-­‐GM-­‐CSF	  treatment	  did	  not	  have	  an	  effect	  on	  the	  ability	  of	  C.	  difficile	  to	  colonize	  in	  
the	  colon,	  but	  that	  it	  did	  lead	  to	  decreased	  inflammation	  and	  immune	  cell	  infiltration,	  as	  
well	  as	  increased	  epithelial	  cell	  damage,	  coinciding	  with	  reduced	  inflammatory	  and	  
epithelial-­‐protective	  gene	  expression.	  These	  results	  provide	  evidence	  that	  GM-­‐CSF	  plays	  
a	  role	  in	  inflammatory	  signaling	  and	  epithelial	  protection	  during	  C.	  difficile	  colitis	  in	  
mice,	  and	  indicate	  that	  more	  research	  into	  GM-­‐CSF	  and	  related	  signaling	  pathways	  
could	  further	  elucidate	  the	  host	  response	  to	  CDI.	  
	  
	  INTRODUCTION	  
Intestinal	  Immune	  System	  Background	  
	   The	  gastrointestinal	  tract	  is	  the	  site	  of	  a	  tremendous	  amount	  of	  host-­‐microbe	  
interactions,	  and	  as	  such,	  it	  contains	  a	  variety	  of	  defense	  factors.	  In	  the	  large	  intestine,	  
the	  first	  level	  of	  defense	  is	  a	  mucosal	  layer,	  generated	  by	  goblet	  cells,	  coating	  the	  
intestinal	  epithelial	  cells	  (1).	  Epithelial	  cells	  produce	  antimicrobial	  peptides	  to	  prevent	  
bacterial	  growth	  (1).	  In	  addition,	  they	  form	  a	  physical	  protective	  barrier,	  separating	  the	  
contents	  of	  the	  intestinal	  lumen	  from	  the	  underlying	  tissue	  layers	  (2).	  They	  also	  play	  a	  
part	  in	  recognizing	  microbes	  and	  stimulating	  host	  response.	  Leukocytes	  lie	  both	  within	  
and	  underneath	  the	  epithelial	  barrier.	  Intraepithelial	  lymphocytes,	  most	  of	  which	  are	  T-­‐
cells,	  produce	  inflammatory	  and	  epithelial-­‐protective	  signals	  (3).	  Lymphocytes	  under	  the	  
epithelium,	  in	  the	  lamina	  propria	  of	  the	  large	  intestine,	  can	  initiate	  both	  inflammatory	  
and	  anti-­‐inflammatory	  responses	  (4).	  Lamina	  propria	  B-­‐cells	  also	  secrete	  IgA,	  which	  
plays	  a	  direct	  role	  in	  modulating	  the	  composition	  of	  the	  microbial	  population	  of	  the	  
large	  intestine,	  known	  as	  the	  microbiota	  (4).	  The	  lamina	  propria	  also	  contains	  
phagocytic	  cells,	  like	  dendritic	  cells	  (DCs),	  which	  help	  to	  determine	  whether	  host	  
response	  will	  be	  anti-­‐inflammatory	  or	  inflammatory,	  and	  macrophages	  to	  destroy	  
pathogens	  (3).	  Together,	  the	  mucus	  layer,	  epithelial	  cell	  membrane,	  and	  underlying	  
immune	  tissue	  make	  up	  the	  defense	  system	  needed	  to	  protect	  the	  gut	  against	  intestinal	  
pathogens.	  
The	  resident	  gut	  microbiota	  plays	  its	  own	  vital	  role	  in	  the	  intestinal	  immune	  
landscape.	  The	  microbiota	  has	  a	  bidirectional	  relationship	  with	  the	  intestinal	  immune	  
	  system;	  the	  microbiota	  influences	  both	  development	  and	  function	  of	  the	  immune	  
system,	  while	  the	  immune	  system	  regulates	  the	  composition	  of	  the	  microbiota	  (5).	  A	  
healthy	  gut	  microbiota	  is	  essential	  to	  the	  development	  and	  balance	  of	  the	  gut-­‐
associated	  lymphoid	  tissues	  (GALTs)	  discussed	  above,	  as	  well	  as	  effector	  T	  cells,	  T	  
regulatory	  cells,	  and	  B	  cells	  (6).	  In	  addition	  to	  contributing	  to	  immune	  development,	  the	  
microbiota	  also	  contributes	  to	  infection	  resistance	  (7).	  Commensal	  bacteria	  compete	  for	  
nutrients	  such	  as	  amino	  acids,	  stunting	  pathogen	  growth	  (7).	  They	  promote	  the	  
epithelial	  barrier	  by	  stimulating	  production	  of	  mucus	  and	  antimicrobial	  peptides	  (such	  
as	  REGIIIγ),	  and	  by	  producing	  their	  own	  metabolites	  that	  block	  pathogens	  (7).	  
Furthermore,	  the	  microbiota	  enhances	  the	  innate	  immune	  response	  by	  stimulating	  
production	  of	  cytokines	  such	  as	  IL-­‐1β	  and	  IL-­‐17,	  and	  facilitates	  the	  adaptive	  immune	  
response	  by	  promoting	  the	  development	  of	  the	  T	  cell	  subsets	  listed	  above	  (7).	  By	  
directly	  competing	  with	  pathogens	  and	  stimulating	  the	  immune	  system,	  the	  microbiota	  
protects	  the	  host	  from	  infection.	  
	   The	  innate	  immune	  response	  is	  a	  large	  component	  of	  intestinal	  immunity.	  The	  
intestinal	  innate	  immune	  system	  is	  able	  to	  specifically	  target	  pathogenic	  bacteria	  while	  
allowing	  the	  indigenous	  microbiota	  to	  flourish	  (8).	  It	  consists	  primarily	  of	  the	  epithelial	  
barrier,	  including	  the	  mucus	  layer	  and	  antimicrobial	  peptides,	  and	  phagocytic	  cells	  in	  the	  
lamina	  propria	  (9).	  Of	  these	  phagocytic	  cells,	  dendritic	  cells	  and	  macrophages	  are	  
especially	  important	  for	  maintaining	  homeostasis	  in	  the	  gut	  (10).	  Their	  functions	  are	  
dictated	  by	  signaling	  factors	  such	  as	  cytokines.	  When	  the	  homeostasis	  of	  the	  intestine	  is	  
compromised	  due	  to	  infection	  or	  epithelial	  damage,	  inflammatory	  pathways	  are	  
	  activated,	  and	  neutrophils,	  macrophages,	  DCs	  and	  T	  cells	  are	  recruited	  in	  large	  numbers	  
to	  the	  intestinal	  barrier	  (9).	  These	  response	  pathways,	  along	  with	  the	  mucus	  layer	  and	  
antimicrobial	  defenses	  of	  the	  epithelium,	  allow	  the	  intestinal	  innate	  immune	  system	  to	  
combat	  infection.	  
One	  of	  the	  factors	  involved	  in	  gut	  innate	  immune	  responses	  is	  the	  cytokine	  
granulocyte-­‐macrophage	  colony-­‐stimulating	  factor	  (GM-­‐CSF,	  also	  known	  as	  CSF2).	  GM-­‐
CSF	  has	  a	  host	  of	  functions,	  including	  promoting	  hematopoietic	  growth,	  promoting	  the	  
survival	  and	  activation	  of	  macrophages,	  neutrophils	  and	  eosinophils,	  and	  mediating	  the	  
maturation	  of	  DCs	  and	  the	  differentiation	  of	  invariant	  natural	  killer	  T	  cells	  (9,	  11).	  GM-­‐
CSF	  usually	  requires	  stimulation	  (e.g.	  infection)	  to	  be	  found	  in	  detectable	  levels	  in	  vivo,	  
and	  it	  is	  produced	  in	  especially	  high	  levels	  when	  the	  intestinal	  inflammatory	  response	  is	  
activated	  (11,	  12).	  A	  variety	  of	  cell	  types	  are	  responsible	  for	  GM-­‐CSF	  production,	  such	  as	  
fibroblasts,	  smooth	  muscle	  cells,	  endothelial	  cells,	  stromal	  cells,	  macrophages	  and	  
osteoblasts—macrophages	  and	  endothelial	  cells	  being	  the	  most	  relevant	  in	  the	  gut,	  as	  
well	  as	  myeloid	  cells	  along	  the	  GI	  tract.	  GM-­‐CSF	  receptors	  are	  found	  mainly	  on	  
macrophages,	  however,	  they	  are	  also	  found	  on	  a	  few	  types	  of	  non-­‐hematopoietic	  cells.	  
Specifically	  in	  terms	  of	  intestinal	  immunity,	  GM-­‐CSF	  is	  important	  because	  of	  its	  function	  
in	  the	  maturation	  of	  hematopoietic	  cells	  and	  maintenance	  of	  the	  intestinal	  barrier.	  
During	  infection,	  GM-­‐CSF	  produced	  in	  the	  intestinal	  mucosa	  regulates	  recruitment	  and	  
survival	  of	  DCs,	  enhancing	  host	  protection	  (13).	  During	  DSS-­‐induced	  colitis,	  GM-­‐CSF	  
increases	  systemic	  and	  mucosal	  type	  1	  IFN	  expression	  as	  part	  of	  the	  immune	  response,	  
but	  causes	  reduced	  expression	  of	  some	  pro-­‐imflammatory	  genes,	  ultimately	  
	  ameliorating	  disease	  (12).	  Overall,	  the	  role	  of	  GM-­‐CSF	  during	  the	  innate	  immune	  
response	  to	  intestinal	  disease	  includes	  granulocyte,	  monocyte,	  and	  dendritic	  cell	  
survival	  and	  maturation,	  pro-­‐inflammatory	  signaling,	  and	  some	  anti-­‐inflammatory	  
signaling	  as	  well.	  
	  
Clostridium	  difficile	  Infection	  
Clostridium	  difficile	  is	  a	  gram-­‐positive,	  spore-­‐forming	  anaerobic	  bacterium,	  which	  
causes	  toxin-­‐mediated	  intestinal	  disease.	  C.	  difficile	  infection	  (CDI)	  can	  result	  in	  an	  array	  
of	  clinical	  outcomes,	  ranging	  from	  asymptomatic	  colonization	  to	  mild	  diarrhea	  and	  
abdominal	  pain	  to	  pseudomembranous	  colitis,	  toxic	  megacolon,	  sepsis,	  shock	  and	  death	  
(14).	  CDI	  develops	  primarily	  after	  antibiotic	  treatment	  disrupts	  the	  intestinal	  microbiota,	  
allowing	  for	  C.	  difficile,	  which	  is	  resistant	  to	  a	  variety	  of	  antibiotics,	  to	  colonize	  the	  gut	  
(15).	  The	  bacteria	  is	  found	  mainly	  in	  infants,	  where	  it	  rarely	  causes	  clinical	  symptoms,	  
and	  in	  elderly	  hospital	  patients	  on	  antibiotics,	  where	  it	  causes	  the	  most	  disease,	  though	  
recently	  it	  has	  also	  emerged	  as	  a	  causative	  agent	  in	  adult	  antibiotic-­‐associated	  diarrhea	  
(14,	  15).	  This	  is	  due	  in	  part	  to	  the	  spore-­‐forming	  nature	  of	  C.	  difficile,	  which	  hinders	  
sanitation	  efforts	  and	  increases	  the	  ease	  of	  transmission	  (16).	  
	   In	  the	  last	  15	  years,	  the	  incidence	  of	  severe	  CDI	  has	  increased	  dramatically.	  From	  
2000	  to	  the	  present,	  the	  number	  of	  CDI	  diagnoses	  have	  increased	  from	  <150,000	  to	  
>500,000	  cases	  per	  year	  in	  the	  US	  alone,	  with	  15,000	  to	  20,000	  of	  these	  cases	  resulting	  
in	  death	  (14).	  This	  is	  costing	  the	  U.S.	  healthcare	  system	  over	  $2	  billion	  per	  year	  (17).	  The	  
most	  prominent	  C.	  difficile	  strain	  in	  North	  American	  infections	  is	  known	  as	  BI/NAP1/027	  
	  (14).	  CDI	  has	  historically	  been	  a	  hospital	  infection,	  but	  in	  recent	  years	  it	  is	  estimated	  that	  
up	  to	  50%	  of	  all	  initial	  CDI	  cases	  were	  onset	  outside	  a	  hospital	  or	  long-­‐term	  care	  facility	  
(17).	  Almost	  all	  infections	  are	  antibiotic/antimicrobial-­‐associated,	  with	  the	  most	  
commonly	  assicated	  medications	  being	  clindamycin,	  cephalosporins	  and	  
fluoroquinolones	  (17).	  	  
	   C.	  difficile	  produces	  two	  large	  virulent	  toxins,	  TcdA	  and	  TcdB,	  which	  cause	  most	  
of	  the	  disease’s	  symptoms	  (14).	  TcdA	  seems	  to	  cause	  more	  severe	  disease	  (i.e.	  intestinal	  
inflammation	  and	  cell	  death)	  in	  animal	  models,	  while	  TcdB	  is	  the	  main	  effector	  of	  
disease	  in	  humans	  (18).	  Both	  toxins	  have	  the	  same	  mechanism:	  disruption	  of	  the	  actin	  
cytoskeleton	  and	  tight	  junctions	  between	  epithelial	  cells,	  leading	  to	  a	  breakdown	  of	  
epithelial	  membrane	  resistance	  (19).	  This	  is	  achieved	  by	  targeting	  host	  GTPases	  which	  
regulate	  actin	  (20).	  The	  C-­‐terminal	  and	  central	  regions	  of	  the	  toxin	  monoglucosylate	  
threonine	  residues	  on	  GTPases,	  inactivating	  them	  and	  leading	  to	  cell	  death	  (21).	  The	  
toxins	  also	  cause	  IECs,	  mast	  cells,	  and	  macrophages	  to	  release	  pro-­‐inflammatory	  
cytokines,	  leading	  to	  fluid	  accumulation	  and	  an	  influx	  of	  neutrophils	  into	  the	  epithelial	  
lumen	  (19,	  22).	  Eventually	  the	  combination	  of	  toxins	  bypassing	  the	  damaged	  barrier	  and	  
the	  inflammatory	  response	  can	  lead	  to	  epithelial	  and	  immune	  cell	  apoptosis	  or	  necrosis	  
and	  further	  mucosal	  damage	  (21).	  
	  
Recent	  Research:	  Intestinal	  Innate	  Immune	  Response	  to	  C.	  difficile	  
	   C	  difficile	  infection	  in	  antibiotic	  pre-­‐treated	  mice	  leads	  to	  the	  development	  of	  
acute	  colitis,	  resulting	  in	  an	  innate	  immune	  response.	  This	  response	  is	  characterized	  by	  
	  neutrophil	  recruitment,	  tissue	  damage,	  increased	  mucosal	  permeability,	  and	  congestion	  
and	  edema	  of	  the	  lamina	  propria	  (23).	  Numerous	  innate	  immune	  sensors	  and	  receptors,	  
including	  the	  inflammasome,	  TLR4,	  TLR5,	  NOD1	  and	  MyD88	  signaling	  pathways	  are	  
required	  to	  protect	  against	  severe	  disease	  (24).	  However,	  the	  blocking	  of	  neutrophil	  
recruitment,	  as	  well	  as	  the	  down-­‐regulation	  of	  various	  other	  inflammatory	  measures,	  
has	  also	  resulted	  in	  increased	  protection	  from	  disease	  (25,	  26).	  Importantly,	  intestinal	  
damage	  seems	  to	  be	  caused	  by	  the	  inflammatory	  response	  itself,	  in	  addition	  to	  the	  
direct	  cell	  damage	  from	  the	  toxin.	  Therefore,	  while	  the	  inflammatory	  response	  is	  
important	  in	  host	  protection,	  overexuberant	  inflammation	  can	  have	  negative	  effects	  
during	  C.	  difficile-­‐induced	  colitis.	  
	   Previous	  research	  from	  our	  laboratory	  has	  shown	  that	  GM-­‐CSF	  expression	  
increases	  during	  C.	  difficile	  infection	  in	  mice	  (27).	  And	  as	  noted	  above,	  GM-­‐CSF	  plays	  a	  
key	  role	  in	  enteric	  innate	  immune	  response	  through	  its	  recruitment	  of	  DCs,	  
macrophages,	  and	  neutrophils,	  and	  epithelial	  maintenance.	  It	  also	  plays	  a	  part	  in	  the	  
inflammatory	  response	  in	  the	  gut.	  Cell	  recruitment,	  epithelial	  damage,	  and	  
inflammation	  are	  characteristic	  of	  C.	  difficile	  infection.	  However,	  the	  role	  of	  GM-­‐CSF	  
during	  C.	  difficile	  infection	  is	  poorly	  understood.	  In	  the	  current	  study,	  we	  have	  used	  the	  
mouse	  model	  previously	  outlined	  by	  Theriot	  et	  al.	  to	  test	  the	  role	  of	  GM-­‐CSF	  signaling	  
during	  C.	  difficile-­‐induced	  colitis	  (28).	  We	  find	  that	  depleting	  GM-­‐CSF	  signaling	  does	  not	  
affect	  C.	  difficile	  colonization,	  but	  does	  lead	  to	  reduced	  epithelial	  inflammation	  and	  
immune	  cell	  recruitment,	  while	  also	  leaving	  epithelial	  cells	  more	  vulnerable	  to	  damage	  
and	  death.	  
	  	  
MATERIALS	  AND	  METHODS	  
Animal	  Housing	  and	  Antibiotic	  Administration	  
C57BL/6	  mice	  obtained	  from	  Jackson	  Laboratories	  (Bar	  Harbor,	  ME)	  were	  used	  to	  
establish	  a	  breeding	  colony	  at	  the	  University	  of	  Michigan	  Medical	  School.	  They	  were	  
housed	  under	  specific	  pathogen-­‐free	  conditions	  and	  consumed	  clean	  food	  and	  water	  ad	  
libitum.	  Male	  mice	  at	  5–8	  weeks	  of	  age	  were	  used	  for	  the	  current	  set	  of	  experiments.	  
Beginning	  a	  week	  prior	  to	  infection,	  mice	  were	  treated	  with	  cefoperazone	  (0.5g/L)	  
(Sigma)	  in	  distilled	  water	  (Gibco)	  for	  5	  days.	  The	  antibiotic	  water	  was	  replaced	  once	  
during	  day	  3.	  After	  antibiotic	  treatment,	  mice	  were	  given	  autoclaved	  drinking	  water	  
without	  antibiotics	  for	  two	  days,	  after	  which,	  C.	  difficile-­‐infected	  animals	  were	  infected	  
with	  630g	  C.	  difficile	  spores.	  Untreated	  mice	  received	  were	  neither	  infected	  nor	  
antibiotic-­‐treated.	  
During	  the	  antibiotic	  treatment	  and	  infection	  period,	  all	  animals	  were	  monitored	  
for	  weight	  change	  once	  daily.	  C.	  difficile	  infected	  mice	  were	  monitored	  for	  symptoms	  of	  
severe	  disease	  and	  humanely	  euthanized	  if	  moribund.	  
	  
Histology	  and	  Necopsy	  
	   Mice	  were	  humanely	  euthanized	  via	  CO2	  asphyxiation	  four	  days	  post-­‐infection.	  
Samples	  were	  collected	  from	  excised	  colon	  tissue.	  Tissue	  for	  subsequent	  DNA	  analysis	  
was	  immediately	  flash	  frozen	  and	  stored	  at	  -­‐80o	  C.	  Tissue	  for	  RNA	  analysis	  was	  stored	  in	  
RNAlater	  solution	  (Ambion).	  The	  remaining	  excised	  colons	  were	  fixed	  in	  10%	  formalin	  
	  solution	  overnight,	  then	  transferred	  to	  70%	  ethanol	  solution.	  Cassettes	  were	  processed,	  
paraffin	  embedded,	  sectioned,	  and	  used	  to	  prepare	  haematoxylin	  and	  eosin	  stained	  
slides	  by	  McClinchey	  Histology	  Lab	  Inc.	  
	  
Spore	  Preparation	  and	  Infection	  
	   Spores	  were	  taken	  from	  a	  stock	  of	  the	  630g	  strain	  of	  C.	  difficile	  (ATCC	  BAA-­‐1382).	  
This	  strain	  was	  chosen	  due	  to	  its	  less	  virulent	  nature,	  which	  allowed	  for	  a	  more	  nuanced	  
look	  at	  changes	  in	  immune	  response.	  The	  infection	  procedure	  was	  adapted	  from	  the	  
model	  set	  forth	  by	  Theriot	  et	  al	  (28).	  The	  spores	  were	  serially	  diluted,	  then	  heated	  to	  
60O	  C	  for	  20	  minutes	  to	  destroy	  any	  residual	  vegetative	  cells.	  Each	  animal	  was	  then	  
infected	  with	  approximately	  5*104	  spores.	  The	  inoculum	  was	  then	  serially	  diluted	  and	  
plated	  on	  tarocholate-­‐cefoxitin-­‐cycloserine-­‐fructose-­‐agar	  (TCCFA)	  plates	  (Anaerobe	  
Systems)	  overnight	  at	  37O	  C	  to	  confirm	  the	  actual	  infectious	  dose.	  
	  
Antibody	  Administration	  
	   Mice	  in	  the	  anti-­‐GM-­‐CSF-­‐treated	  group	  were	  given	  intraperitoneal	  injections	  of	  
monoclonal	  anti-­‐GM-­‐CSF	  antibody	  MP1-­‐22E9	  mixed	  with	  sterile	  saline	  as	  previously	  
described	  in	  the	  literature	  (29,	  30).	  Each	  mouse	  received	  a	  total	  of	  250	  ug	  of	  antibody	  
per	  injection.	  Injections	  were	  given	  every	  other	  day,	  beginning	  one	  day	  pre-­‐infection	  
and	  concluding	  three	  days	  post-­‐infection.	  Mice	  in	  the	  untreated	  and	  CDI-­‐treated	  control	  
groups	  were	  not	  given	  injections.	  
	  
	  RNA	  Isolation	  and	  Gene	  Expression	  Analysis	  
RNA	  isolation	  and	  gene	  expression	  analysis	  were	  conducted	  as	  previously	  
described	  (26).	  Colon	  snips	  obtained	  during	  necropsy	  were	  homogenized	  into	  TRIzol	  
RNA	  reagent	  (Life	  Technologies).	  An	  RNeasy	  Mini	  kit	  (Qiagen)	  was	  used	  according	  to	  
manufacturer	  instructions	  to	  isolate	  RNA	  from	  the	  samples.	  An	  Agilent	  Bioanalyser	  
(Aglilent	  Technologies)	  and	  a	  Nanodrop	  instrument	  (Thermo	  Fisher)	  were	  used	  to	  
determine	  quality	  and	  concentration	  of	  isolated	  RNA,	  respectively.	  Complementary	  DNA	  
(cDNA)	  was	  generated	  from	  isolated	  RNA	  using	  an	  RT2	  First	  Strand	  kit	  (Qiagen).	  Gene	  
expression	  levels	  were	  measured	  using	  a	  custom	  mouse	  RT2	  Profiler	  PCR	  card	  (Qiagen)	  
containing	  twelve	  replicated	  sets	  of	  32	  primer	  pairs.	  Each	  well	  was	  loaded	  with	  cDNA	  
reaction	  product.	  The	  card	  was	  run	  on	  a	  LightCycler	  480	  RT-­‐PCR	  system	  (Roche).	  Relative	  
RNA	  expression	  levels	  were	  determined	  from	  Ct	  values.	  
	  
DNA	  Isolation	  and	  Quantification	  of	  C.	  difficile	  Colonization	  
	   DNA	  was	  isolated	  from	  colon	  snips	  obtained	  during	  necropsy	  using	  a	  DNeasy	  kit	  
(Qiagen)	  according	  to	  manufacturer	  instructions.	  C.	  difficile	  colonization	  was	  measured	  
using	  species-­‐specific	  qPCR	  of	  isolated	  colon	  DNA.	  Each	  10	  μL	  reaction	  included	  2	  μL	  of	  
isolated	  DNA,	  6.25	  pmol	  F/R-­‐TcdB	  primers,	  and	  1	  pmol	  TcdB	  probe.	  The	  following	  cycling	  
conditions	  were	  used:	  Activation	  for	  1	  cycle,	  95o	  C	  for	  15	  minutes;	  Cycling	  for	  45	  cycles	  
of	  95o	  C	  for	  15	  seconds,	  60o	  C	  for	  20	  seconds,	  and	  72o	  C	  for	  10	  seconds;	  Hold	  for	  30	  
seconds	  at	  72o	  C.	  Raw	  Ct	  values	  were	  normalized	  to	  mouse	  TNFα	  gene	  content,	  used	  as	  a	  
single-­‐copy	  host	  internal	  control	  gene,	  to	  generate	  ΔCt	  values.	  ΔCt	  values	  were	  then	  
	  converted	  to	  “detectable	  genomes/g	  host	  tissue”	  using	  a	  standard	  curve.	  The	  standard	  
curve	  was	  generated	  by	  calculating	  ΔCt	  values	  for	  samples	  containing	  known	  amounts	  of	  
vegetative	  C.	  difficile	  cells	  and	  mouse	  colonic	  tissue.	  
	  
RESULTS	  
C.	  difficile	  Colitis	  in	  the	  Absence	  of	  GM-­‐CSF	  Signaling	  	  
	   We	  first	  wanted	  to	  examine	  the	  effect	  that	  the	  loss	  of	  GM-­‐CSF	  signaling	  has	  on	  C.	  
difficile	  colonization	  of	  the	  large	  intestine.	  Mice	  were	  given	  cefaperazone	  drinking	  water	  
(0.5	  g/L)	  for	  five	  days	  (Figure	  1).	  Two	  days	  after	  the	  end	  of	  antibiotic	  treatment,	  mice	  
were	  challenged	  with	  approximately	  5*104	  colony-­‐forming	  units	  of	  C.	  difficile.	  The	  
infection	  was	  allowed	  to	  progress	  for	  4	  days,	  and	  colonic	  tissue	  was	  harvested.	  Next,	  
qPCR	  was	  used	  to	  determine	  the	  level	  of	  colonization	  of	  the	  experimental	  groups.	  qPCR	  
results	  were	  originally	  calculated	  as	  ΔCt	  values,	  corresponding	  to	  the	  difference	  in	  signal	  
between	  the	  target	  C.	  difficile	  sequence	  and	  a	  single-­‐copy	  host	  gene.	  We	  established	  a	  
standard	  curve	  to	  convert	  ΔCt	  values	  into	  units	  of	  CFU	  of	  C.	  difficile	  per	  gram	  of	  mouse	  
tissue.	  Colonic	  tissue	  samples	  from	  untreated	  mice	  were	  weighed	  to	  determine	  the	  
tissue	  mass.	  A	  series	  of	  dilutions	  containing	  known	  quantities	  of	  C.	  difficile	  were	  added	  
to	  the	  tissue	  samples.	  Then,	  a	  species-­‐specific	  quantitative	  polymerase	  chain	  reaction	  
(qPCR)	  was	  used	  to	  determine	  the	  ΔCt	  values	  that	  corresponded	  to	  the	  concentration	  of	  
bacteria	  per	  gram	  of	  host	  tissue.	  The	  result	  was	  a	  standard	  curve	  that	  allowed	  for	  
conversion	  of	  ΔCt	  values	  from	  qPCR	  into	  a	  more	  useful	  metric	  for	  determining	  
colonization,	  CFU	  per	  gram	  of	  colonic	  tissue.	  
	  Untreated	  animals	  were	  not	  detectably	  colonized	  with	  C.	  difficile.	  C.	  difficile	  
infected	  wild-­‐type	  and	  C.	  difficile	  infected	  anti-­‐GM-­‐CSF	  treated	  animals	  were	  colonized	  
with	  approximately	  1.5*105	  and	  5*104	  CFU	  of	  C.	  difficile	  per	  gram	  of	  colonic	  tissue,	  
respectively	  (Figure	  2).	  Both	  infected	  groups	  had	  statistically	  significantly	  higher	  
colonization	  than	  the	  untreated	  group,	  as	  determined	  by	  an	  ANOVA	  test.	  Notably,	  there	  
was	  no	  significant	  difference	  in	  colonization	  levels	  between	  the	  two	  infected	  groups.	  
These	  results	  provide	  evidence	  that	  depletion	  of	  GM-­‐CSF	  signaling	  does	  not	  significantly	  
affect	  the	  ability	  of	  C.	  difficile	  to	  colonize	  in	  the	  large	  intestine	  of	  cefaperazone-­‐treated	  
mice.	  They	  also	  confirm	  that	  this	  model	  is	  useful	  in	  studying	  disease	  caused	  by	  C.	  
difficile,	  because	  the	  pathogen	  loads	  were	  equivalent	  between	  the	  infected	  groups.	  
The	  first	  measure	  of	  disease	  that	  we	  examined	  was	  weight	  loss.	  Mice	  were	  
monitored	  for	  weight	  changes	  for	  seven	  days	  before	  inoculation,	  and	  four	  days	  after.	  All	  
experimental	  groups	  showed	  consistent	  weight	  gain	  (5-­‐7%	  of	  initial	  body	  weight)	  for	  the	  
first	  seven	  days,	  regardless	  of	  antibiotic	  treatment	  (Figure	  3).	  During	  the	  four	  days	  after	  
infection,	  untreated	  animals	  continued	  to	  gain	  weight	  (~2%	  of	  initial	  body	  weight),	  while	  
C.	  difficile	  infected	  animals	  lost	  ~8%	  of	  body	  weight	  during	  the	  peak	  of	  infection,	  around	  
three	  days	  after	  exposure	  to	  the	  bacteria.	  Interestingly,	  anti-­‐GM-­‐CSF	  treated	  mice	  with	  
CDI	  displayed	  intermediate	  weight	  loss,	  losing	  ~5%	  of	  initial	  body	  weight	  during	  the	  peak	  
of	  infection.	  While	  both	  the	  CDI	  and	  anti-­‐GM-­‐CSF	  CDI	  groups	  displayed	  a	  sharp	  weight	  
loss	  during	  the	  first	  three	  days	  of	  infection,	  mice	  treated	  with	  anti-­‐GM-­‐CSF	  antibody	  
trended	  toward	  less	  weight	  loss	  than	  the	  wild-­‐type	  group,	  indicating	  that	  anti-­‐GM-­‐CSF	  
treatment	  may	  reduce	  the	  weight	  loss	  caused	  by	  CDI.	  
	  	  
Histopathology	  Changes	  Due	  to	  Anti-­‐GM-­‐CSF	  Treatment	  during	  CDI	  
	   We	  next	  wanted	  to	  examine	  the	  effect	  of	  anti-­‐GM-­‐CSF	  treatment	  on	  intestinal	  
damage	  during	  C.	  difficile	  colitis.	  Examination	  of	  intestinal	  histopathology	  revealed	  that	  
uninfected	  animals	  showed	  signs	  of	  healthy	  colonic	  epithelial	  tissue,	  as	  characterized	  by	  
a	  lack	  of	  tissue	  damage	  and	  inflammatory	  cell	  infiltration	  (Figures	  4A	  and	  4B,	  left).	  C.	  
difficile-­‐infected	  wild-­‐type	  mice	  developed	  typical	  signs	  of	  C.	  difficile-­‐induced	  disease,	  
including	  inflammatory	  cell	  recruitment	  and	  submucosal	  edema	  (Figure	  4A,	  middle,	  
black	  arrows).	  Remarkably,	  anti-­‐GM-­‐CSF	  treated	  mice	  displayed	  much	  less	  inflammatory	  
cell	  infiltration	  into	  epithelial	  tissue,	  indicating	  a	  decrease	  in	  inflammatory	  response	  in	  
the	  absence	  of	  GM-­‐CSF	  signaling	  (Figure	  4A,	  right,	  black	  arrows).	  As	  expected,	  wild-­‐type	  
mice	  also	  some	  exhibited	  signs	  of	  colonic	  epithelial	  cell	  damage	  (Figure	  4B,	  middle).	  
Notably,	  treatment	  with	  anti-­‐GM-­‐CSF	  caused	  increased	  epithelial	  damage	  beyond	  
normal	  levels	  seen	  in	  wild-­‐type	  mice	  (Figure	  4B,	  right,	  grey	  arrows).	  This	  data	  suggests	  
that	  GM-­‐CSF	  signaling	  not	  only	  promotes	  inflammatory	  signaling,	  but	  also	  has	  some	  
epithelial	  protective	  function	  during	  C.	  difficile	  colitis.	  
	  
Inflammatory	  Gene	  Expression	  in	  the	  Absence	  of	  GM-­‐CSF	  Signaling	  
	   In	  order	  to	  further	  examine	  the	  trends	  seen	  in	  the	  histology	  slides,	  we	  next	  
investigated	  the	  effect	  of	  anti-­‐GM-­‐CSF	  treatment	  on	  the	  expression	  of	  inflammatory	  
genes.	  Isolated	  RNA	  from	  colonic	  tissue	  of	  untreated,	  CDI	  treated,	  and	  anti-­‐GM-­‐CSF	  CDI	  
treated	  mice	  was	  analyzed	  as	  describe	  in	  Materials	  and	  Methods.	  Along	  with	  the	  
	  inflammatory	  cell	  recruitment	  seen	  in	  the	  CDI	  groups,	  increased	  expression	  of	  various	  
pro-­‐inflammatory	  cytokine	  genes	  was	  detected	  in	  these	  animals	  (Figure	  5A).	  Strikingly,	  
and	  consistent	  with	  the	  reduced	  epithelial	  cell	  infiltration	  noted	  in	  the	  histopathological	  
analysis,	  anti-­‐GM-­‐CSF	  treated	  mice	  showed	  reduced	  expression	  of	  pro-­‐inflammatory	  
genes.	  Tnfα	  expression	  in	  GM-­‐CSF-­‐depleted	  mice	  was	  just	  1.2-­‐fold	  higher	  than	  
untreated	  animals,	  compared	  to	  a	  nearly	  5	  fold	  change	  in	  wild-­‐type	  mice.	  Il-­‐1β	  showed	  a	  
less	  dramatic,	  but	  still	  significant	  drop	  in	  expression	  in	  GM-­‐CSF-­‐depleted	  mice	  versus	  
wild-­‐type	  mice.	  Ifng	  displayed	  an	  intermediate	  phenotype	  in	  GM-­‐CSF-­‐depleted	  mice;	  
expression	  was	  not	  significantly	  higher	  than	  in	  untreated	  animals,	  but	  not	  significant	  
lower	  than	  wild-­‐type.	  
	   We	  observed	  a	  similar	  pattern	  in	  inflammatory	  chemokine	  expression	  as	  well.	  
Infection	  of	  wild-­‐type	  animals	  resulted	  in	  increased	  expression	  of	  Cxcl1,	  Cxcl2,	  Cxcl10,	  
Ccl2,	  and	  Ccl4	  (Figure	  5B).	  However,	  in	  mice	  treated	  with	  anti-­‐GM-­‐CSF,	  chemokine	  Ccl4	  
displayed	  an	  intermediate	  phenotype,	  while	  Cxcl2	  expression	  was	  significantly	  reduced	  
compared	  to	  the	  wild	  type.	  Taken	  together,	  these	  data	  strongly	  suggest	  that	  GM-­‐CSF	  
signaling	  drives	  inflammatory	  cytokine	  and	  chemokine	  gene	  expression	  during	  C.	  difficile	  
colitis.	  
	  
Epithelial	  Protective	  Gene	  Expression	  in	  the	  Absence	  of	  GM-­‐CSF	  Signaling	  
	   In	  addition	  to	  inflammatory	  cytokines	  and	  chemokines	  genes,	  we	  also	  wished	  to	  
investigate	  the	  effect	  of	  reduced	  GM-­‐CSF	  signaling	  on	  the	  expression	  of	  genes	  involved	  
in	  epithelial	  protection.	  Gene	  expression	  data	  confirmed	  that	  Reg3γ	  and	  SLPI	  were	  
	  significantly	  up-­‐regulated	  during	  C.	  difficile	  infection	  in	  wild-­‐type	  mice	  (Figure	  6).	  Reg3γ	  
is	  an	  antimicrobial	  peptide;	  SLPI	  is	  a	  protease	  inhibitor	  that	  protects	  the	  host	  from	  its	  
own	  defensive	  enzymes.	  In	  addition,	  NOS2,	  which	  codes	  for	  nitric	  oxide	  synthase,	  and	  is	  
also	  involved	  in	  epithelial	  protection,	  was	  significantly	  up-­‐regulated.	  Reg3γ	  expression	  
levels	  in	  GM-­‐CSF-­‐depleted	  mice	  were	  comparable	  to	  wild-­‐type	  mice,	  but	  both	  SLPI	  and	  
NOS2	  levels	  were	  significantly	  lower	  in	  the	  GM-­‐CSF-­‐depleted	  group,	  which	  is	  consistent	  
with	  the	  increased	  epithelial	  damage	  seen	  in	  the	  histopathology	  analysis	  (Figure	  4).	  
These	  data	  suggest	  that	  GM-­‐CSF	  plays	  a	  role	  in	  epithelial	  protection	  during	  C.	  difficile	  
infection,	  and	  support	  the	  histological	  data	  showing	  that	  reduced	  GM-­‐CSF	  signaling	  
results	  in	  more	  epithelial	  damage	  during	  infection.	  
	  
DISCUSSION	  
	   The	  current	  study	  was	  undertaken	  in	  order	  to	  examine	  the	  role	  of	  GM-­‐CSF	  
signaling	  during	  C.	  difficile	  colitis.	  Pathogen	  colonization	  was	  confirmed	  by	  quantifying	  
detectable	  C.	  difficile	  genomes	  and	  murine	  colonic	  cells	  via	  qPCR	  and	  comparing	  the	  
levels	  to	  a	  standard	  growth	  curve.	  Anti-­‐GM-­‐CSF	  depletion	  was	  shown	  to	  have	  no	  
significant	  effect	  on	  levels	  of	  colonization,	  validating	  the	  utility	  of	  this	  experimental	  
model	  in	  studying	  disease	  due	  caused	  by	  equivalent	  C.	  difficile	  burden.	  Weight	  loss	  data	  
provided	  evidence	  that	  anti-­‐GM-­‐CSF	  treatment	  may	  reduce	  the	  severity	  of	  disease	  due	  
to	  CDI.	  The	  effect	  of	  GM-­‐CSF	  depletion	  on	  infection	  was	  investigated	  using	  histological	  
preparations	  of	  colonic	  tissue	  to	  look	  at	  microscopic	  changes	  in	  the	  epithelial	  tissue,	  and	  
an	  RT-­‐qPCR	  assay	  to	  assess	  changes	  in	  gene	  expression.	  When	  GM-­‐CSF	  signaling	  was	  
	  ablated	  through	  the	  use	  of	  a	  depleting	  antibody,	  we	  observed	  decreased	  cellular	  
infiltrate.	  Consistently,	  we	  also	  observed	  reduced	  expression	  of	  pro-­‐inflammatory	  
myeloid	  cell	  chemokines	  in	  GM-­‐CSF-­‐depleted	  mice.	  Anti-­‐GM-­‐CSF	  treatment	  also	  caused	  
an	  increase	  in	  epithelial	  cell	  damage,	  coinciding	  with	  a	  decrease	  in	  expression	  of	  genes	  
involved	  in	  epithelial	  protection.	  This	  data	  supports	  the	  conclusion	  the	  GM-­‐CSF	  serves	  
both	  pro-­‐inflammatory	  and	  protective	  functions	  during	  C.	  difficile	  infection	  in	  mice.	  
	   The	  histological	  data	  from	  this	  study	  provides	  evidence	  for	  decreased	  neutrophil	  
and	  monocyte	  recruitment	  during	  CDI	  due	  to	  GM-­‐CSF	  depletion,	  which	  is	  consistent	  
with	  the	  role	  of	  GM-­‐CSF	  as	  a	  granulocyte	  and	  macrophage	  stimulating	  cytokine	  (Figure	  
4).	  Neutrophil	  and	  monocyte	  (especially	  macrophage)	  recruitment	  are	  well-­‐documented	  
hallmarks	  of	  the	  intestinal	  immune	  response	  to	  C.	  difficile	  (27,	  31,	  32).	  Histopathology	  
analysis	  also	  showed	  an	  increase	  in	  damage	  to	  epithelial	  cells	  in	  the	  absence	  of	  GM-­‐CSF	  
(Figure	  4).	  Together,	  these	  results	  indicate	  that	  GM-­‐CSF	  may	  play	  a	  role	  in	  the	  
inflammatory	  response	  and	  epithelial	  protective	  response	  to	  CDI.	  
	   The	  gene	  expression	  data	  from	  this	  study	  indicated	  significant	  down-­‐regulation	  
of	  notable	  pro-­‐inflammatory	  cytokines	  and	  chemokines	  in	  C.	  difficile	  infected	  tissue	  in	  
the	  absence	  of	  GM-­‐CSF	  signaling,	  as	  compared	  to	  infected	  wild-­‐type	  mice.	  TNFα,	  which	  
was	  reduced	  to	  almost	  baseline	  levels	  due	  to	  GM-­‐CSF	  depletion,	  is	  involved	  in	  
neutrophil	  recruitment	  during	  airway	  epithelial	  inflammation,	  and	  is	  connected,	  along	  
with	  Il-­‐22,	  to	  neutrophil	  recruitment	  in	  response	  to	  intestinal	  colitis	  (33,	  34).	  Il-­‐22	  
expression	  was	  not	  significantly	  higher	  in	  infected	  GM-­‐CSF-­‐depleted	  mice	  than	  in	  
untreated	  mice,	  while	  it	  was	  significantly	  higher	  in	  infected	  wild-­‐type	  mice,	  indicating	  
	  that	  anti-­‐GM-­‐CSF	  treatment	  reduces	  both	  TNFα	  and	  IL-­‐22.	  	  CXCL2,	  which	  produces	  a	  
chemokine	  that	  also	  contributes	  to	  neutrophil	  infiltration	  during	  C.	  difficile	  colitis,	  was	  
also	  significantly	  downregulated	  (35).	  It	  can	  be	  concluded	  from	  these	  data	  that	  GM-­‐CSF	  
plays	  a	  role	  in	  neutrophil	  recruitment	  during	  C.	  difficile	  colitis,	  likely	  due	  to	  decreased	  
expression	  of	  TNFα,	  IL-­‐22,	  and	  CXCL2.	  
Il-­‐1β,	  which	  codes	  for	  a	  pro-­‐inflammatory	  cytokine	  known	  to	  cause	  intestinal	  
tight	  junction	  permeability,	  was	  also	  downregulated	  upon	  GM-­‐CSF	  depletion	  (36).	  
Disruption	  of	  tight	  junctions	  is	  a	  staple	  of	  C.	  difficile	  colitis,	  but	  it	  is	  possible	  that	  it	  is	  
toxin-­‐mediated	  and	  not	  due	  to	  Il-­‐1β	  (21).	  IFNγ	  displayed	  an	  intermediate	  phenotype,	  
showing	  a	  trend	  of	  lower	  expression	  when	  GM-­‐CSF	  was	  depleted.	  Interferon-­‐gamma	  has	  
been	  shown	  to	  be	  a	  key	  mediator	  of	  TcdA-­‐induced	  colitis	  due	  to	  its	  attenuation	  of	  TNFα	  
and	  chemokine	  secretion,	  and	  so	  this	  result	  could	  warrant	  more	  investigation	  (37).	  
These	  results	  all	  suggest	  that	  in	  addition	  to	  stimulating	  neutrophil	  recruitment,	  GM-­‐CSF	  
could	  be	  a	  part	  of	  the	  inflammatory	  response	  during	  CDI	  through	  a	  variety	  of	  other	  
routes.	  
GM-­‐CSF	  depletion	  also	  has	  an	  effect	  on	  the	  expression	  of	  genes	  involved	  in	  
epithelial	  protection.	  SPLI,	  which	  had	  significantly	  lower	  expression	  in	  GM-­‐CSF-­‐depleted	  
mice,	  encodes	  a	  protease	  inhibitor	  that	  limits	  tissue	  damage	  and	  facilitates	  healing	  
during	  colitis	  (38).	  NOS2	  expression	  was	  also	  reduced	  in	  the	  absence	  of	  GM-­‐CSF.	  NOS2	  
produces	  nitric	  oxide,	  which	  is	  essential	  for	  the	  antimicrobial	  properties	  of	  macrophages	  
(39).	  Taken	  together,	  this	  data	  indicates	  that	  knocking	  out	  GM-­‐CSF	  signaling	  during	  CDI	  
reduces	  the	  expression	  of	  epithelial	  protective	  genes.	  
	  In	  the	  current	  study,	  we	  have	  investigated	  the	  role	  of	  GM-­‐CSF	  signaling	  in	  the	  
innate	  immune	  response	  to	  C.	  difficile	  colitis.	  However,	  the	  nature	  of	  the	  cellular	  
infiltrate	  and	  the	  sources	  and	  targets	  of	  GM-­‐CSF	  signaling	  during	  CDI	  remain	  unknown.	  
Thus,	  further	  work	  is	  required.	  Broadening	  the	  variety	  of	  genes	  examined	  could	  reveal	  
other	  key	  signaling	  molecules	  involved	  in	  the	  innate	  response	  to	  C.	  difficile.	  The	  addition	  
of	  an	  experimental	  group	  with	  overexpression	  of	  GM-­‐CSF	  could	  strengthen	  the	  
connections	  between	  GM-­‐CSF	  and	  other	  signaling	  and	  protective	  molecules	  that	  have	  
been	  indicated	  in	  this	  work.	  Histological	  scoring	  would	  allow	  for	  a	  more	  quantitative	  
look	  at	  microscopic	  damage	  to	  the	  intestinal	  epithelium,	  and	  could	  confirm	  that	  anti-­‐
GM-­‐CSF	  treatment	  reduces	  inflammation	  and	  increases	  epithelial	  cell	  damage.	  Flow	  
cytometry	  of	  colonic	  tissue	  samples	  would	  be	  very	  advantageous	  in	  assessing	  the	  
changes	  in	  inflammatory	  cell	  population	  in	  response	  to	  changes	  in	  GM-­‐CSF	  signaling	  
levels,	  with	  the	  expectation	  that	  fewer	  neutrophils	  and	  macrophages	  would	  be	  present	  
when	  GM-­‐CSF	  signaling	  is	  reduced.	  Microbiome	  sequencing	  could	  be	  useful	  in	  detecting	  
changes	  in	  the	  commensal	  bacteria	  due	  to	  depletion	  of	  GM-­‐CSF,	  both	  before	  and	  during	  
infection,	  which	  could	  have	  an	  effect	  on	  the	  course	  of	  the	  disease.	  Based	  on	  the	  clear	  
connections	  between	  GM-­‐CSF	  and	  the	  inflammatory	  response	  to	  C.	  difficile	  laid	  out	  in	  
this	  work,	  more	  investigation	  is	  warranted	  to	  further	  understand	  the	  intestinal	  innate	  




	  FIGURE	  1:	  Experimental	  Timeline	  
	   A	  timeline	  for	  C.	  difficile	  infection	  of	  anti-­‐GM-­‐CSF	  treated	  mice.	  See	  Materials	  
and	  Methods	  for	  a	  detailed	  description.	  
FIGURE	  2:	  Effect	  of	  Infection	  of	  Body	  Weight	  
	   The	  effect	  of	  C.	  difficile	  infection	  following	  five	  day	  cefaperazone	  treatment	  on	  
mouse	  body	  weight.	  Baseline	  body	  weight	  was	  determined	  prior	  to	  antibiotic	  treatment,	  
one	  week	  before	  infection.	  Mice	  were	  weighed	  again	  two	  days	  pre-­‐infection,	  the	  day	  of	  
infection,	  and	  every	  day	  for	  four	  days	  post-­‐infection.	  Plotted	  points	  with	  error	  bars	  
represent	  mean	  body	  weight	  ±	  SEM	  from	  three	  independent	  experiments	  with	  n=8	  per	  
group.	  
FIGURE	  4:	  C.	  difficile	  Colonization	  
	   C.	  difficile	  colonization	  of	  colonic	  tissue	  following	  cefaperazone	  treatement.	  
Colonization	  of	  C.	  difficile	  was	  quantified	  by	  species-­‐specific	  qPCR,	  the	  signal	  from	  which	  
was	  converted	  to	  detectable	  C.	  difficile	  genomes	  per	  gram	  of	  mouse	  colonic	  tissue	  
through	  the	  use	  of	  a	  pre-­‐establish	  standard	  curve	  [see	  Materials	  and	  Methods].	  Bars	  
represent	  mean	  ±	  SEM	  from	  three	  independent	  experiments	  with	  n=8	  per	  group.	  The	  
limit	  of	  detection	  is	  approximately	  104	  CFU/g.	  
FIGURE	  5:	  Histopathology	  of	  Mouse	  Colonic	  Tissue	  
	   Photomicrographs	  of	  haemotoxylin	  and	  eosin	  stained	  colon	  epithelial	  tissue.	  
Colonic	  tissue	  was	  removed	  during	  necropsy	  and	  preserved	  in	  formalin,	  then	  ethanol.	  
Black	  arrowheads	  indicate	  cellular	  infiltrate;	  gray	  arrowheads	  indicate	  epithelial	  damage	  
due	  to	  C.	  difficile	  colitis.	  Magnification	  100x.	  
	  FIGURE	  6:	  Inflammatory	  Gene	  Expression	  
	   Changes	  in	  colonic	  inflammatory	  gene	  expression	  during	  C.	  difficile	  colitis	  due	  to	  
GM-­‐CSF	  depletion.	  Colonic	  gene	  expression	  was	  measured	  using	  reverse	  transcriptase	  
quantitative	  PCR	  assays.	  A)	  Inflammatory	  cytokine	  expression	  B)	  Inflammatory	  
chemokine	  expression.	  Asterisks	  indicate	  a	  statistically	  significant	  increase	  in	  gene	  
expression	  compared	  to	  untreated	  expression	  levels.	  Brackets	  indicate	  a	  statistically	  
significant	  difference	  in	  expression	  between	  CDI-­‐treated	  and	  GM-­‐CSF-­‐depleted	  CDI-­‐
treated	  groups	  for	  the	  denoted	  gene.	  Bars	  represent	  mean	  ±	  SEM	  from	  three	  
independent	  experiments	  with	  n=8	  per	  group.	  
FIGURE	  7:	  Epithelial	  Protective	  Gene	  Expression	  
	   Changes	  in	  colonic	  epithelial	  protection	  gene	  expression	  during	  C.	  difficile	  colitis	  
due	  to	  GM-­‐CSF	  depletion.	  Colonic	  gene	  expression	  was	  measured	  using	  reverse	  
transcriptase	  quantitative	  PCR	  assays.	  Asterisks	  indicate	  a	  statistically	  significant	  
increase	  in	  gene	  expression	  compared	  to	  untreated	  expression	  levels.	  Brackets	  indicate	  
a	  statistically	  significant	  difference	  in	  expression	  between	  CDI-­‐treated	  and	  GM-­‐CSF-­‐
depleted	  CDI-­‐treated	  groups	  for	  the	  denoted	  gene.	  Bars	  represent	  mean	  ±	  SEM	  from	  
three	  independent	  experiments	  with	  n=8	  per	  group.	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